ClinicalTrials.gg
RecruitingNCT06872866Updated Nov 19, 2025

The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects

A Phase 1 interventional study of ASP-001.1 and ASP-001.1 in Erectile Dysfunction, sponsored by Aspargo Labs, Inc. Recruiting at 1 site in United States. Open to male participants aged 20 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Aspargo Labs, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 180 studies in Erectile Dysfunction with a site in United States — 26 open to participants now, 31 under way, 3 of them phase 3. Erectile Dysfunction · United States.

Planned enrollment
135th of 164
12 · median 75
Started
2025
with 6 others
Phase 1
20 of 180
3 open now
Primary completion
2026-02
later than 5 of 30 live
Registered
171st of 180
by date

Among the 180 studies in Erectile Dysfunction with a site in United States, this one is the 135th largest by planned enrollment of the 164 interventional ones that give a count, is one of 7 that started in 2025, is one of 20 in phase 1, reaches primary completion later than 5 of the 30 other live ones, and was the 171st registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

26 of the 180 studies in Erectile Dysfunction with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 20 Years to 70 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies in Erectile Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The objective of this phase 1 study is to evaluate the food effect of 100 mg Hezkue Turbo® (ASP-001.1, sildenafil) under fed versus 100 mg of Hezkue Turbo® (ASP-001.1, sildenafil) under fasted conditions in healthy adult male subjects

Read the detailed description

This is a Phase 1, open-label, single-center, two-period, two-treatment crossover study designed to evaluate the pharmacokinetics (PK), food effect, safety, and tolerability of ASP-001.1 (oral liquid suspension of sildenafil) under fed versus fasted conditions in healthy adult male participants. The crossover design ensures that each participant receives ASP-001.1 under both fed and fasted conditions, allowing for direct within-subject comparison of the pharmacokinetic parameters. The study aims to determine the effect of food on the absorption and bioavailability of ASP-001.1 and to assess its safety and tolerability, including the potential for oral irritation, dizziness, or headache.

Subjects will be randomly assigned to one of two sequences for the crossover study:

  • Sequence 1: ASP-001.1 under fasted conditions in Treatment Period 1, followed by ASP-001.1 under fed conditions in Treatment Period 2.
  • Sequence 2: ASP-001.1 under fed conditions in Treatment Period 1, followed by ASP-001.1 under fasted conditions in Treatment Period 2.

Randomization will occur after screening and prior to Treatment Period 1 dosing.

03

Conditions studied

  • Erectile Dysfunction

Browse trials for

Keywords

  • erectile dysfunction
  • viagra
  • sildenafil
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant must be informed of the nature of the study and voluntarily agree to participate by signing an form prior to any study-specific procedures.
  • Participants must be healthy male volunteers aged 20 to 70 years (inclusive) at the time of dosing.
  • Participants must have a between 18.0 and 29.9 kg/m² (inclusive) and a body weight of 50 to 100 kg (inclusive).
  • Participants must be judged by the Investigator or designee to be in good general health, as documented by medical history, physical examination, clinical laboratory tests, vital signs, and 12-lead (ECG). Any deviations from normal ranges must be assessed and deemed not by the Investigator or designee.
  • Participants must have a (CrCl) value greater than 80 mL/min, as calculated by the Cockcroft-Gault equation.
  • Participants must agree to practice an acceptable method of as outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness or inability to follow the procedures specified by the protocol.
  • Participant received any drug/product within 30 days prior to the first dose.
  • History of significant renal, hepatic, cardiovascular (including orthostatic hypotension), psychiatric, neoplastic, inflammatory, infectious, diabetes mellitus, or other disease which, in the opinion of the Investigator, represents a safety risk for taking part in the study.
  • Presence of any results from laboratory tests, vital signs assessments, and , as judged by the Investigator and/or designee.
  • Any degree of hepatic impairment based on liver function testing (abnormal , AST, , alkaline phosphatase, and international normalized ratio during screening).
  • Demonstrates a reactive screen for surface antigen, antibody, or antibody.
  • Reports a clinically significant illness during the 28 days prior to first dose (as determined by the Investigator and/or designee).
  • Subjects with known to sildenafil or any component in the study medication, such as peppermint oil.
  • Reports a history of clinically significant allergies including food or drug allergies as judged by the Investigator.
  • History of drug abuse within the previous year, or a positive drug screen (amphetamines, barbiturates, benzodiazepines, cannabinoids, Cocaine, Opiates, Phencyclidine, 3,4-methylenedioxymethamphetamine (MDMA)) at screening and/or Day -1.
  • Regular alcohol consumption of >15 units per week, with one unit being equivalent to 330 mL of beer or 125 mL of wine or 25 mL to 40 mL of ≥ 40% spirits, or a positive alcohol breathalyzer test at screening and/or Day -1.
  • Reports use of CYP enzyme inhibitors within 14 days prior to Period 1 dosing.
  • Reports use of CYP enzyme inducers or St. John's Wort within 28 days prior to Period 1 dosing.
  • Use of prescription or non-prescription drugs, including individual vitamins, herbal and dietary supplements within seven days or five half-lives, whichever is longer, unless in the opinion of the Investigator and Sponsor's medical monitor the medication is not expected to interfere with the study procedures or compromise subject safety (occasional use of acetaminophen, naproxen, and ibuprofen are allowed).
  • Blood donation or significant blood loss within 3 months before screening. All volunteers will be advised not to donate blood for 30 days after completing the study.
  • Reports donating plasma within 14 days prior to first dose. All volunteers will be advised not to donate plasma for 30 days after completing the study.
  • Demonstrates, in the opinion of study staff, inadequate veins or veins unsuitable for repeated venipuncture (e.g., veins difficult to locate, access, or puncture; veins with a tendency to rupture during or after puncture).
  • Reports difficulty fasting or consuming standardized meals.
  • Reports intolerance to fatty foods or cannot consume a high-calorie and high-fat breakfast.
  • Subjects who have difficulty swallowing.
  • Regular use of tobacco (>4 cigarettes per day) or nicotine-containing products within four weeks before screening, or urinary cotinine level indicative of active smoking at screening and/or Day -1
  • Major surgery within three months or minor surgery within one month before screening as per the Principal Investigator (PI) judgment.
  • If, in the opinion of the PI, the subject is not suitable for the study.
  • Subject administered COVID-19 vaccine within three days prior to each check-in.
  • Subjects with retainers, braces, dentures, partial dentures, and/or tongue piercing.
  • Subjects using the following within 14 days of first dose:
  • Nitric oxide donors, such as organic nitrates or organic nitrites in any form
  • Antihypertensive medications
  • PDE5 inhibitors (e.g., sildenafil, tadalafil, vardenafil)

Subjects with known hypertension or blood pressure and heart rate outside of the following ranges:

  • Systolic blood pressure: 90 - 140 mmHg
  • Diastolic blood pressure: 50 - 90 mmHg
  • Heart rate at screening: 50 - 100 beats per minute
  • Institutionalized volunteers.
  • Reports use of any hormone replacement therapy within 6 months prior to first dose.
  • Use of any products containing Seville oranges, grapefruit and pomelo within seven days prior to first dose and for the duration of the study.
  • Ingestion of any caffeine/xanthine containing products (coffee, tea, soft drinks, chocolate, energy drinks, etc.), foods containing poppy seeds within 48 hours prior to first dose and for the duration of the study.
  • Ingestion of any beverages containing more than 5% fruit juice (fruit drinks, fruit punches, fruit cocktails, fruit-ades, or other products containing 5% or less of fruit juice will be allowed) within 48 hours prior to first dose and for the duration of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Arm 1 - Fasted vs Fed Conditions

    Participants receive 100mg of ASP-001.1 first under fasted conditions and under fed conditions after

    Drug: ASP-001.1 · Device: ASP-001.1

  • Experimental
    Arm 2- Fed vs Fasted Conditions

    Participants receive 100mg of ASP-001.1 first under fed conditions and under fasted conditions after

    Drug: ASP-001.1 · Device: ASP-001.1

Interventions

  • DrugASP-001.1

    Oral liquid suspension of sildenafil

  • DeviceASP-001.1

    Bottle/pump containing ASP-001.1 suspension

06

What researchers measure

Primary outcomes

  1. Cmax

    The PK profile of ASP-001.1 in healthy male subjects under fasted vs fed conditions. Calculation of maximum plasma concentration (Cmax) over the specified timeframe.

    Time frame: Baseline and at 26 different timepoints during the 24 hour post-dose

  2. AUCt

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. The area under the plasma concentration versus time curve from zero to infinity (AUCi) will be calculated by adding the last quantifiable concentration (Ct)/ elimination rate contant (Kel) to AUCt.

    Time frame: Baseline and at 26 different timepoints during the 24 hour post-dose

  3. Tmax

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. Calculation of the time of the maximum measured plasma concentration (Tmax). If the maximum plasma concentration occurs at more than one time point, the first is chosen as Tmax.

    Time frame: Baseline and at 26 different timepoints during the 24 hour post-dose

  4. Thalf

    PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. The half-life will be calculated by the equation tHalf = 0.693/ Kel. Apparent elimination half-life.

    Time frame: Baseline and at 26 different timepoints during the 24 hour post-dose

  5. Kel

    The PK of ASP-001.1 in healthy male subjects under fasted and fed conditions. Calculation of the terminal elimination rate constant obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) of the concentration versus time plot for these timepoints.

    Time frame: Baseline and at 26 different timepoints during the 24 hour post-dose

Secondary outcomes

  1. Number of participants with oral irritation, dizziness, or headache

    To determine the potential of ASP-001.1 to cause oral irritation, dizziness, or headache. Descriptive summaries (mean, standard deviation (SD), median, minimum, and maximum) of actual values and changes from baseline will be provided.

    Time frame: Baseline and different timepoints during the 24 hour post-dose

  2. Number of participants with adverse events

    The frequency and type of adverse events reported during the study.

    Time frame: Baseline and at several timepoints during the 24h post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2026, 10 months after the start.

Of 18 phase 1 interventional studies under Erectile Dysfunction, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 19. This study's planned 10 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2025
First posted
Mar 12, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06872866
Lead sponsor
Aspargo Labs, Inc
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
Apr 15, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2026 (estimated)
Last update
Nov 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion